Literature DB >> 1513914

Cognitive behavior therapy and relapse of nonbipolar depression: parallels with pharmacotherapy.

M E Thase1, A D Simons.   

Abstract

The risk of relapse was studied in 44 major depressives following successful acute treatment with cognitive behavior therapy (CBT). Patients entered a 1-year prospective followup with independent clinical assessments at 1, 3, 6, 9, and 12 months. Of these patients, 15 (34%) relapsed; correlates included marital status, recurrent subtype, higher initial and residual ratings of depressive severity, and slower response to therapy. Both married status (p = .008) and fully recovered status (p = .02) were significantly and independently related to decreased risk of relapse using the Cox proportional hazard method. These findings provide further documentation of a relationship between residual symptomatology and relapse after cessation of active treatment and closely parallel findings pertaining to risk of relapse after acute antidepressant pharmacotherapy of unipolar depression. As in pharmacotherapy, a longer period of continuation treatment may be indicated for patients at risk for relapse after an initial course of time-limited therapy with CBT.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1513914

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  3 in total

1.  Psychotherapies in residency training.

Authors:  S Hamilton; L A Mellman; G O Gabbard; M E Thase; J C Markowitz
Journal:  J Psychother Pract Res       Date:  1999

2.  The prognostic significance of subsyndromal symptoms emerging after remission of late-life depression.

Authors:  D N Kiosses; G S Alexopoulos
Journal:  Psychol Med       Date:  2012-05-21       Impact factor: 7.723

3.  Vortioxetine vs. Other Antidepressants in Patients with Major Depressive Episode With or Without Substance Use Disorder.

Authors:  Georgios D Kotzalidis; Ginevra Lombardozzi; Marta Matrone; Emanuela Amici; Filippo Perrini; Ilaria Cuomo; Sergio De Filippis
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.708

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.